VITASPRING BIOMEDICAL CO., LTD.: 10-Q filed 2021-06-14
What VITASPRING BIOMEDICAL CO., LTD. reported in its quarterly report filed 2021-06-14 (fiscal Q1 2022): 21 published measures, 41 facts as tagged in accession 0001697884-21-000007.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-06-14
- Fiscal period
- fiscal Q1 2022
- Accession
- 0001697884-21-000007 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VITASPRING BIOMEDICAL CO., LTD. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 460,509 | USD | |
| At 2020-01-31 | 189,398 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 367,130 | USD | |
| At 2020-01-31 | 96,364 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 367,130 | USD | |
| At 2021-01-31 | 96,364 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 404,257 | USD | |
| At 2020-04-30 | 893 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 235,662 | USD | 89 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 533,800 | USD | 89 |
| 2020-02-01 to 2020-04-30 | 0 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-04 to 2021-04-30 | 358,859 | USD | 86 |
| 2020-02-04 to 2020-04-30 | 893 | USD | 87 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | -211,616 | USD | |
| At 2020-01-31 | -447,278 | USD |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 205,418,001 | shares | 89 |
| 2020-02-01 to 2020-04-30 | 10,902,006 | shares | 90 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 56,252 | USD | 89 |
| 2020-02-01 to 2020-04-30 | 0 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 235,662 | USD | 89 |
| 2020-02-01 to 2020-04-30 | -17,745 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 404,257 | USD | |
| At 2020-01-31 | 189,398 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 93,379 | USD | |
| At 2020-01-31 | 93,034 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 239,800 | USD | 89 |
| 2020-02-01 to 2020-04-30 | 0 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 198,385,015 | shares | |
| At 2020-01-31 | 209,670,030 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 794,753 | USD | |
| At 2020-01-31 | 814,899 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 56,252 | USD | |
| At 2021-01-31 | 0 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 0 | USD | 89 |
| 2020-02-01 to 2020-04-30 | 0 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 60,390 | USD | 89 |
| 2020-02-01 to 2020-04-30 | 17,745 | USD | 90 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-04 to 2021-04-30 | -56,252 | USD | 86 |
| 2020-02-04 to 2020-04-30 | 0 | USD | 87 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-04 to 2021-04-30 | 0 | USD | 86 |
| 2020-02-04 to 2020-04-30 | 0 | USD | 87 |
Inspect the source
- Entity
- VITASPRING BIOMEDICAL CO., LTD. / CIK 0001697884
- Captured
- 2026-09-21T17:23:44.772Z
- SEC response SHA-256
ee15de6dda3aedafc6c6b7ee7d9d21edb5e0091bf01dcbaec55b3fe460e6f43a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001697884.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))